Evidence map›Paper›PMID 28148575›Full record

ReviewClinical medicine (London, England)2017

Chronic respiratory disease - the acceptable epidemic?

Peter Burney

Abstract readReview
In one paragraph

Review in Clinical medicine (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Towards precision in defining COPD exacerbations.Breathe (Sheffield, England) · 2021
    Review
  5. Article
  6. The Impact ofIn vivo (Athens, Greece)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Peter BurneyNational Heart and Lung Institute, Imperial College, London, UK p.burney@imperial.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic obstructive pulmonary disease (COPD) is a major cause of disability and death in the UK but is an even greater problem in low income countries. It is assumed by many to be almost entirely attributed to smoking. However, smoking alone cannot account for the distribution of the disease in the world and there is accumulating evidence that the disease is overwhelmingly a disease of poverty. The size of the problem and the failure of current hypotheses to explain the distribution of chronic lung disease make the lack of funding in this area surprising. The failure of science funders to respond to the analysis of the Cooksey report, which pointed out the extreme discrepancy between the size of the problem and the paucity of research funding, represents a serious failure in science policy. The lack of urgency in the face of such a large burden of illness suggests a degree of complacency in the face of a disease that is overwhelmingly a disease of the poor.

Indexed as

Pulmonary Disease, Chronic ObstructiveCost of IllnessHumansPovertyUnited KingdomCOPDdisease burdenlung functionpolicypoverty

Identifiers

PMID28148575
PMCPMC6297588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.